FindTrial
Sign In

Investigation of factors associated with changes in urinary albumin when SGLT2 inhibitor, tofogliflozin, is initially administered or readministered to type 2 diabetic patients with stage 2-3 diabetic nephropathy

Subanalysis of RESTORE-nephropathy study (the research to explore the effects of a SGLT2 inhibitor, tofogliflozin, on renal protection estimated by first administration and readministration in patients with stage 2-3 diabetic nephropathy) - Subanalysis of RESTORE-nephropathy study

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000061329
Enrollment
47
Registered
2026-05-01
Start date
2026-05-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stage 2-3 diabetic nephropathy

Interventions

None listed

Sponsors

Japan society for patient reported outcome
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Individuals with type 2 diabetes mellitus and stage 2 or 3 diabetic nephropathy

Exclusion criteria

Exclusion criteria: Individuals with type 1 diabetes or secondary diabetes, individuals with a history of SGLT2 inhibitor use, individuals who started to use or changed the dose of angiotensin-converting enzyme inhibitors or angitotensin receptor blockers within 3 months before giving their informed consent.

Design outcomes

Primary

MeasureTime frame
Correlation between changes in 2 fractions of urinary metanephrine (metanephrine, normetanephrine) and nrinary albumin (creatinine conversion, UACR) from baseline (0 week) to 60th week.—

Countries

Japan

Contacts

Public ContactMasami Tanaka

Japan society for patient reported outcome Not available

info@jpro.jp03-6626-5140

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026